CN119700941A - 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法 - Google Patents

长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法 Download PDF

Info

Publication number
CN119700941A
CN119700941A CN202411943619.6A CN202411943619A CN119700941A CN 119700941 A CN119700941 A CN 119700941A CN 202411943619 A CN202411943619 A CN 202411943619A CN 119700941 A CN119700941 A CN 119700941A
Authority
CN
China
Prior art keywords
conjugate
cells
acting
receptor agonist
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411943619.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·B·基尔科
张平
P·K·布鲁尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CN119700941A publication Critical patent/CN119700941A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202411943619.6A 2017-05-15 2018-05-15 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法 Pending CN119700941A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201762506494P 2017-05-15 2017-05-15
US62/506,494 2017-05-15
US201762536966P 2017-07-25 2017-07-25
US62/536,966 2017-07-25
US201762582186P 2017-11-06 2017-11-06
US62/582,186 2017-11-06
US201862648240P 2018-03-26 2018-03-26
US62/648,240 2018-03-26
CN201880032373.3A CN111093688B (zh) 2017-05-15 2018-05-15 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
PCT/US2018/032817 WO2018213341A1 (en) 2017-05-15 2018-05-15 Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880032373.3A Division CN111093688B (zh) 2017-05-15 2018-05-15 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法

Publications (1)

Publication Number Publication Date
CN119700941A true CN119700941A (zh) 2025-03-28

Family

ID=64274790

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411943619.6A Pending CN119700941A (zh) 2017-05-15 2018-05-15 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
CN201880032373.3A Active CN111093688B (zh) 2017-05-15 2018-05-15 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880032373.3A Active CN111093688B (zh) 2017-05-15 2018-05-15 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法

Country Status (10)

Country Link
US (2) US12036283B2 (enExample)
EP (1) EP3624827A4 (enExample)
JP (3) JP7316222B2 (enExample)
KR (2) KR102798243B1 (enExample)
CN (2) CN119700941A (enExample)
AU (2) AU2018270926C1 (enExample)
CA (1) CA3060410A1 (enExample)
IL (2) IL318018A (enExample)
MX (2) MX2019013621A (enExample)
WO (1) WO2018213341A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202011308VA (en) 2018-05-14 2020-12-30 Werewolf Therapeutics Inc Activatable cytokine polypeptides and methods of use thereof
JP7460609B2 (ja) 2018-05-14 2024-04-02 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なインターロイキン－２ポリペプチド及びその使用方法
EP3876974A4 (en) * 2018-11-09 2022-11-23 Nektar Therapeutics LONG-ACTING INTERLEUKIN-15 RECEPTOR AGONIST IN COMBINATION WITH ANOTHER PHARMACOLOGICALLY ACTIVE AGENT
KR20210149090A (ko) * 2019-04-05 2021-12-08 넥타르 테라퓨틱스 세포 면역요법을 향상시키기 위한 방법
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
JP7762570B2 (ja) 2019-05-20 2025-10-30 サイチューン ファーマ 癌又は感染性疾患を処置するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト投薬レジメン
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
US20230398185A1 (en) 2020-10-26 2023-12-14 Cytune Pharma Il-2/il-15r-beta-gamma agonist for treating non-melanoma skin cancer
JP2023550685A (ja) 2020-10-26 2023-12-05 サイチューン ファーマ 扁平上皮癌を治療するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト
JP2024526080A (ja) 2021-06-23 2024-07-17 サイチューン ファーマ インターロイキン１５多様体
EP4384204A1 (en) 2021-08-13 2024-06-19 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
AU2024221783A1 (en) * 2023-02-14 2025-07-31 Akron Bioproducts Llc Interleukin formulations for in vivo use
WO2024215989A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
AU1096595A (en) 1993-11-12 1995-05-29 Gilead Sciences, Inc. Thrombin mutants
ATE196315T1 (de) 1994-04-06 2000-09-15 Immunex Corp Interleukin-15
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7008624B1 (en) 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
CA2323048C (en) 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
AU2001238595A1 (en) 2000-02-22 2001-09-03 Shearwater Corporation N-maleimidyl polymer derivatives
JP2006519170A (ja) 2002-12-26 2006-08-24 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
MXPA05007348A (es) 2003-01-06 2005-10-05 Nektar Therapeutics Al Corp Derivados de polimeros solubles en agua tiol-selectivos.
JP2007506789A (ja) 2003-09-25 2007-03-22 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１を用いた自己免疫疾患の治療方法
WO2006020849A2 (en) 2004-08-11 2006-02-23 Beth Israel Deaconess Medical Center, Inc. Mutant interleukin-15 polypeptides
CA2583274A1 (en) 2004-10-05 2007-02-15 Ochsner Clinic Foundation Enhancement of b cell proliferation by il-15
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
WO2006138572A2 (en) 2005-06-16 2006-12-28 Nektar Therapeutics Al, Corporation Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
WO2008106186A2 (en) 2007-02-28 2008-09-04 Serina Therapeutics, Inc. Activated polyoxazolines and compositions comprising the same
EP2237799B1 (en) 2008-02-01 2019-04-10 Ascendis Pharma A/S Prodrug comprising a self-cleavable linker
MX2011003117A (es) * 2008-09-19 2011-04-21 Nektar Therapeutics Conjugados polimericos de peptidos terapeuticos.
DK2431741T3 (da) 2008-10-21 2013-10-21 Baxter Int Fremgangsmåde til bestemmelse af virksomme bestanddele i profarmaka-PEG-proteinkonjugat
KR102325780B1 (ko) 2010-07-30 2021-11-12 박스알타 인코퍼레이티드 옥심 결합용 친핵성 촉매
RS61854B1 (sr) 2010-11-12 2021-06-30 Nektar Therapeutics Konjugati il-2 dela i polimera
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (en) 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
WO2014201378A1 (en) 2013-06-13 2014-12-18 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
CN107001438A (zh) 2014-10-14 2017-08-01 阿尔莫生物科技股份有限公司 白细胞介素‑15组合物及其用途
US12233104B2 (en) * 2015-10-08 2025-02-25 Nektar Therapeutics Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist

Also Published As

Publication number Publication date
EP3624827A1 (en) 2020-03-25
AU2018270926C1 (en) 2022-10-27
WO2018213341A1 (en) 2018-11-22
CN111093688B (zh) 2025-09-16
US12036283B2 (en) 2024-07-16
IL270634B1 (en) 2025-02-01
IL318018A (en) 2025-02-01
KR20200003922A (ko) 2020-01-10
KR102798243B1 (ko) 2025-04-18
CN111093688A (zh) 2020-05-01
AU2022203691A1 (en) 2022-06-16
MX2019013621A (es) 2020-01-13
CA3060410A1 (en) 2018-11-22
JP7316222B2 (ja) 2023-07-27
MX2024009988A (es) 2024-08-27
US20240424115A1 (en) 2024-12-26
US20200078467A1 (en) 2020-03-12
JP2020519676A (ja) 2020-07-02
AU2018270926B2 (en) 2022-04-07
EP3624827A4 (en) 2021-03-03
JP2025111770A (ja) 2025-07-30
IL270634B2 (en) 2025-06-01
JP2023082218A (ja) 2023-06-13
KR20250057110A (ko) 2025-04-28
AU2018270926A1 (en) 2019-11-07
IL270634A (en) 2019-12-31
AU2022203691B2 (en) 2023-10-12
JP7772733B2 (ja) 2025-11-18

Similar Documents

Publication Publication Date Title
CN111093688B (zh) 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
JP6728055B2 (ja) Ｉｌ−１５部分とポリマーとのコンジュゲート
JP2018154644A (ja) Ｉｌ−２部分とポリマーとのコンジュゲート
KR20170125839A (ko) Ｉｌ-7 부분 및 중합체의 접합체
IL312646A (en) SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS
WO2022020637A1 (en) Il-7 receptor agonist composition and related methods and uses
EA043667B1 (ru) Длительно действующие агонисты рецептора интерлейкина-15, связанные с ними композиции и способы их получения и применения
US20250270273A1 (en) Polymer engineered forms of interferon-gamma and methods of use
HK1235666A1 (en) Conjugates of il-15 and branched polyethylene glycol

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination